CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm

SIMPLE SUMMARY: Until recently, there were no approved therapies for the aggressive blood cancer blastic plasmacytoid dendritic cell neoplasm (BPDCN). Survival for patients diagnosed with BPDCN is under two years, and improved treatments are needed. In 2018, tagraxofusp became the first approved dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Bôle-Richard, Elodie, Pemmaraju, Naveen, Caël, Blandine, Daguindau, Etienne, Lane, Andrew A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099711/
https://www.ncbi.nlm.nih.gov/pubmed/35565416
http://dx.doi.org/10.3390/cancers14092287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099711/
https://www.ncbi.nlm.nih.gov/pubmed/35565416
http://dx.doi.org/10.3390/cancers14092287

Ejemplares similares